Arcutis Biotherapeutics, Inc. ARQT Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenue, net by Product | ||||||
| ZORYVE Cream0.05 | $1.36M— | —— | —— | —— | $0— | |
| ZORYVE Cream0.15 | $21.74M+113% | $24.49M+228% | $18.95M+673% | $14.62M— | $10.22M— | |
| ZORYVE Cream0.3 | $32.67M+39.7% | $39.44M+28.2% | $30.49M+38.3% | $27.68M+60.4% | $23.39M+55.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Arcutis Biotherapeutics, Inc. break its business down?
- Arcutis Biotherapeutics, Inc. (ARQT) reports product revenue, net by product across 3 parts — ZORYVE Cream0.05, ZORYVE Cream0.15 and ZORYVE Cream0.3. Each is extracted from the segment footnotes and tracked over time.
- Where does Arcutis Biotherapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Arcutis Biotherapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.